Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Multiple Sclerosis Centers of Excellence

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Fingolimod (Gilenya®)

Fingolimod (Gilenya®) is the first oral agent approved by the FDA in 2010 as a disease modifying treatment for MS. It is given at a dose of .5mg capsule taken once per day by mouth with or without food. It is a new class of MS medication called a sphingosine 1-phosphate receptor modulator. The medication mechanism of action can reduce neurodegeneration by reducing inflammatory damage to nerve cells. Side effects patients may develop include bradycardia, atrioventricular block, hypotension and other cardiac manifestations. Patients must be followed closely after an initial dose to recognize and treat these events if they occur. Other adverse events which require further investigation include development of macular edema, neoplasms and infections. Individuals who have questions about Fingolimod (Gilenya) should contact their healthcare provider.

For more information, refer to the articles below:

Fingolimod (Gilenya®) 2012 Update 

Fingolimod (Gilenya®) FDA News

Fingolimod (Gilenya®): Criteria for Use - June 2012 update

 

 

 

 

 

 

 

 

 

Date Updated: May 21, 2012